CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
CCTG is very happy to introduce our patient focused trial webpages that have been developed for recent CCTG trials open to patient enrollment. The goal for this content is to provide CCTG trial specific plain language information for patients and their families that can be used to enhance discussions with their health care team.
A new webpage has been created for members to access the most up-to-date ID.me information. You can now find the direct link to the ID.me updates on the CCTG website in the "Toolbox" under "Updates".
The new direct link can be found here: https://www.ctg.queensu.ca/private/member-updates/IDme if your team needs to bookmark the information.
Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data
A unique, patient focused trial aims to explore if people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer with a better quality of life if they start treatment earlier. If someone is diagnosed with CLL or SLL they may not have major symptoms and treatment is often started when they show symptoms such as fever, anemia, or night sweats.
The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.
